Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
Phase 2 Terminated
15 enrolled 11 charts
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
Phase 2 Terminated
1 enrolled 7 charts
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Terminated
4 enrolled 10 charts
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Phase 2 Terminated
4 enrolled 8 charts
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Phase 2 Terminated
5 enrolled
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Phase 2 Terminated
1 enrolled 9 charts
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
Phase 2 Terminated
2 enrolled 8 charts
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Terminated
46 enrolled 18 charts
GVAX vs. Placebo for MDS/AML After Allo HSCT
Phase 2 Terminated
123 enrolled 26 charts
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Phase 2 Terminated
41 enrolled 13 charts
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
Phase 2 Terminated
10 enrolled
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Phase 2 Terminated
32 enrolled
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
Phase 2 Terminated
135 enrolled 17 charts
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Phase 2 Terminated
15 enrolled 8 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
Phase 2 Terminated
24 enrolled 17 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Phase 2 Terminated
1 enrolled 6 charts
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase 2 Terminated
6 enrolled 5 charts
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
Phase 2 Terminated
34 enrolled 12 charts
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
Phase 2 Terminated
22 enrolled 11 charts
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Phase 2 Terminated
16 enrolled 6 charts
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
Phase 2 Terminated
3 enrolled
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Phase 2 Terminated
8 enrolled 11 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Phase 2 Terminated
42 enrolled 8 charts
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
Phase 2 Terminated
1 enrolled 6 charts
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Phase 2 Terminated
5 enrolled 5 charts